Targeted Treatment for Cutaneous T-Cell Lymphoma
Name of the Trial
Why This Trial Is Important
Researchers are testing the effectiveness of an immunotoxin called LMB-2 in killing CTCL cells. LMB-2 is a laboratory-created monoclonal antibody fragment attached to a bacterial toxin. It binds to a protein called CD25, which is found on the surface of many human lymphocytes. CD25 is also present on CTCL cells in approximately half of all cases, where it appears more abundantly than on normal lymphocytes. The greater abundance of CD25 allows LMB-2 to target malignant T lymphocytes with great specificity. Once LMB-2 binds to CD25 on the cell surface, the toxin is taken up by the lymphocytes, causing them to die.
Patients will receive up to 6 courses of LMB-2 over approximately 6 months, providing their disease does not progress. Patients who respond completely to LMB-2 may receive further treatment.
"In a phase I trial of LMB-2 that involved patients with a variety of hematologic malignancies," said Dr. Kreitman, "the only patient with CTCL had a clinically significant partial response lasting more than 6 months."
Who Can Join This Trial
Study Site and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.